Want to join the conversation?
$ISRG 2Q15 Call: Procedures grew just under 14% over second quarter of 2014; we placed 118 da Vinci surgical systems up from 96 in second quarter of 2014. Total pro forma revenue was 586MM, up 16% from the prior year &up 20% YoverY on a constant currency basis. Total pro forma instrument & accessory revenue increased to 297MM up 13% over prior year
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?